Literature DB >> 15528274

Interaction between insulin-like growth factor-I receptor and alphaVbeta3 integrin linked signaling pathways: cellular responses to changes in multiple signaling inputs.

D R Clemmons1, L A Maile.   

Abstract

Integrins are heterodimeric transmembrane proteins that mediate cell attachment to extracellular matrix, migration, division, and inhibition of apoptosis. Because growth factors are also important for these processes, there has been interest in cooperative signaling between growth factor receptors and integrins. IGF-I is an important growth factor for vascular cells. One integrin, alphaVbeta3, that is expressed in smooth muscle cells modulates IGF-I actions. Ligand occupancy of alphaVbeta3 is required for IGF-I to stimulate cell migration and division. Src homology 2 containing tyrosine phosphatase (SHP-2) is a tyrosine phosphatase whose recruitment to signaling molecules is stimulated by growth factors including IGF-I. If alphaVbeta3 ligand occupancy is inhibited, there is no recruitment of SHP-2 to alphaVbeta3 and its transfer to downstream signaling molecules is blocked. Ligand occupancy of alphaVbeta3 stimulates tyrosine phosphorylation of the beta3-subunit, resulting in recruitment of SHP-2. This transfer is mediated by an insulin receptor substrate-1-related protein termed DOK-1. Subsequently, SHP-2 is transferred to another transmembrane protein, SHPS-1. This transfer requires IGF-I receptor-mediated tyrosine phosphorylation of SHPS-1, which contains two YXXL motifs that mediate SHP-2 binding. The transfer of SHP-2 to SHPS-1 is also required for recruitment of Shc to SHPS-1. Ligand occupancy of alphaVbeta3 results in sustained Shc phosphorylation and enhanced Shc recruitment. Shc activation results in induction of MAPK. Inhibition of the Shc/SHPS-1 complex formation results in failure to achieve sustained MAPK activation and an attenuated mitogenic response. Thus, within the vessel wall, a mechanism exists whereby ligand occupancy of the alphaVbeta3 integrin is required for assembly of a multicomponent membrane signaling complex that is necessary for cells to respond optimally to IGF-I.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528274     DOI: 10.1210/me.2004-0376

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  32 in total

1.  Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.

Authors:  Gang Xi; Xinchun Shen; Yashwanth Radhakrishnan; Laura Maile; David Clemmons
Journal:  Endocrinology       Date:  2010-06-09       Impact factor: 4.736

2.  Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2010-11-01       Impact factor: 5.285

3.  Insulin resistance in striated muscle-specific integrin receptor beta1-deficient mice.

Authors:  Haihong Zong; Claire C Bastie; Jun Xu; Reinhard Fassler; Kevin P Campbell; Irwin J Kurland; Jeffrey E Pessin
Journal:  J Biol Chem       Date:  2008-12-08       Impact factor: 5.157

Review 4.  Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1.

Authors:  Yoshikazu Takada; Yoko K Takada; Masaaki Fujita
Journal:  Cytokine Growth Factor Rev       Date:  2017-02-03       Impact factor: 7.638

5.  Beta integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation.

Authors:  Nicholas J Anthis; Jacob R Haling; Camilla L Oxley; Massimiliano Memo; Kate L Wegener; Chinten J Lim; Mark H Ginsberg; Iain D Campbell
Journal:  J Biol Chem       Date:  2009-10-20       Impact factor: 5.157

Review 6.  The roles of integrins in mediating the effects of mechanical force and growth factors on blood vessels in hypertension.

Authors:  Jun-Tzu Chao; Michael J Davis
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

7.  Insulin-like growth factor (IGF) signaling requires αvβ3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation.

Authors:  Masaaki Fujita; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2012-12-14       Impact factor: 5.157

8.  Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease?

Authors:  Zongwei Wang; Aria F Olumi
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-08

9.  Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis.

Authors:  Alan C Rapraeger; Brian J Ell; Madhuchhanda Roy; Xuehui Li; Orrianne R Morrison; Grant M Thomas; DeannaLee M Beauvais
Journal:  FEBS J       Date:  2013-02-11       Impact factor: 5.542

Review 10.  Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.

Authors:  Alan C Rapraeger
Journal:  FEBS J       Date:  2013-02-24       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.